JP2017513516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513516A5 JP2017513516A5 JP2017501094A JP2017501094A JP2017513516A5 JP 2017513516 A5 JP2017513516 A5 JP 2017513516A5 JP 2017501094 A JP2017501094 A JP 2017501094A JP 2017501094 A JP2017501094 A JP 2017501094A JP 2017513516 A5 JP2017513516 A5 JP 2017513516A5
- Authority
- JP
- Japan
- Prior art keywords
- microorganism
- cancer
- recombinant chimeric
- group
- chimeric adi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010082340 Arginine deiminase Proteins 0.000 claims 22
- 244000005700 microbiome Species 0.000 claims 16
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 241000064099 Massilioclostridium coli Species 0.000 claims 2
- 241000196746 Mycoplasma columbinum Species 0.000 claims 2
- 241001291198 Mycoplasma iners Species 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 241001148547 Mycoplasma gallinarum Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005462 imide group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954929P | 2014-03-18 | 2014-03-18 | |
| US61/954,929 | 2014-03-18 | ||
| PCT/US2015/021189 WO2015143006A1 (en) | 2014-03-18 | 2015-03-18 | Engineered chimeric pegylated adi and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513516A JP2017513516A (ja) | 2017-06-01 |
| JP2017513516A5 true JP2017513516A5 (enExample) | 2018-04-26 |
| JP6612316B2 JP6612316B2 (ja) | 2019-11-27 |
Family
ID=54145261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501094A Active JP6612316B2 (ja) | 2014-03-18 | 2015-03-18 | 操作されたキメラｐｅｇ化ａｄｉ及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10463721B2 (enExample) |
| EP (1) | EP3119421B1 (enExample) |
| JP (1) | JP6612316B2 (enExample) |
| KR (2) | KR102353046B1 (enExample) |
| CN (1) | CN106794229B (enExample) |
| SG (1) | SG11201607736UA (enExample) |
| WO (1) | WO2015143006A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2805360T3 (es) | 2013-03-15 | 2021-02-11 | Tdw Group | Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer |
| US10463721B2 (en) | 2014-03-18 | 2019-11-05 | Tdw Group | Engineered chimeric pegylated ADI and methods of use |
| SG10202002557SA (en) * | 2014-09-16 | 2020-04-29 | Tdw Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
| CN109414426B (zh) | 2016-07-05 | 2024-12-20 | 北极星药业集团股份有限公司 | 使用精氨酸耗竭剂的组合癌症免疫疗法 |
| CA3039796A1 (en) * | 2016-11-02 | 2018-05-11 | Polaris Group | Formulations of pegylated arginine deiminase |
| CN106591270B (zh) * | 2017-01-23 | 2018-09-21 | 江南大学 | 一株定点突变改造的基因工程精氨酸脱亚胺酶 |
| WO2018183671A1 (en) * | 2017-03-29 | 2018-10-04 | Tdw Group | Protein conjugates |
| US12508306B2 (en) | 2018-04-25 | 2025-12-30 | Washington University | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders |
| WO2022063178A1 (en) * | 2020-09-23 | 2022-03-31 | The Hong Kong Polytechnic University | Fluorescent biosensor for rapid determination of l-arginine |
| KR102640230B1 (ko) * | 2021-09-24 | 2024-02-22 | 가천대학교 산학협력단 | C-peptide를 처리한 자궁내막 기질세포의 이동성 변화 기작을 이용한 자궁내막 관련질환의 진단 방법 및 자궁내막 관련질환 치료제의 스크리닝 방법 |
| EP4580657A2 (en) * | 2022-09-02 | 2025-07-09 | Polaris Group | Modified arginine deiminases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
| US5372942A (en) | 1992-02-10 | 1994-12-13 | Coriell Institute For Medical Research | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent |
| US5804183A (en) * | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
| US6635462B1 (en) | 1997-05-12 | 2003-10-21 | Phoenix Pharmacologies, Inc. | Mutated form of arginine deiminase |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US6180387B1 (en) * | 1997-08-11 | 2001-01-30 | Smithkline Beecham Corporation | Arginine deiminase |
| IT1298918B1 (it) | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| WO2002009741A1 (en) | 2000-07-27 | 2002-02-07 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
| AU2001289132A1 (en) * | 2000-11-28 | 2002-06-11 | Phoenix Pharmacologics, Inc. | Modified arginine deiminase |
| CA2506244C (en) | 2002-11-18 | 2012-10-30 | Phoenix Pharmacologics, Inc. | Methods for inhibiting viral replication in vivo |
| CA2524173A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| WO2005052145A2 (en) * | 2003-10-07 | 2005-06-09 | University Of Florida | Recombinant alkaliizing bacteria |
| CN101002945B (zh) | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| EP2173732A4 (en) | 2007-07-04 | 2011-09-07 | Reddys Lab Ltd Dr | PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC |
| US20090238813A1 (en) | 2007-12-28 | 2009-09-24 | Board Of Regents, The University Of Texas System | Compositions And Methods For Engineered Human Arginine Deiminases |
| WO2010083312A2 (en) | 2009-01-14 | 2010-07-22 | The Trustees Of The University Of Pennsylvania | Micro-rna biomarker in cancer |
| US20110111403A1 (en) | 2009-10-30 | 2011-05-12 | Life Technologies Corporation | Multi-primer assay for mycoplasma detection |
| WO2011151704A2 (en) | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
| US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| US8663967B2 (en) | 2011-08-22 | 2014-03-04 | Jiangsu T-Mab Biopharma Co., Ltd. | Arginine deiminase mutant and preparation and application thereof |
| CN103797025B (zh) | 2012-04-04 | 2018-03-23 | 波拉里集团 | 用精氨酸脱亚氨酶治疗的方法 |
| ES2805360T3 (es) | 2013-03-15 | 2021-02-11 | Tdw Group | Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer |
| US10463721B2 (en) | 2014-03-18 | 2019-11-05 | Tdw Group | Engineered chimeric pegylated ADI and methods of use |
| SG10202002557SA (en) | 2014-09-16 | 2020-04-29 | Tdw Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
-
2015
- 2015-03-18 US US15/125,833 patent/US10463721B2/en active Active
- 2015-03-18 KR KR1020167028878A patent/KR102353046B1/ko active Active
- 2015-03-18 JP JP2017501094A patent/JP6612316B2/ja active Active
- 2015-03-18 SG SG11201607736UA patent/SG11201607736UA/en unknown
- 2015-03-18 WO PCT/US2015/021189 patent/WO2015143006A1/en not_active Ceased
- 2015-03-18 CN CN201580022377.XA patent/CN106794229B/zh active Active
- 2015-03-18 EP EP15765975.6A patent/EP3119421B1/en active Active
- 2015-03-18 KR KR1020227001440A patent/KR102523031B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513516A5 (enExample) | ||
| RU2015141932A (ru) | Аргининдеиминаза с пониженной перекрестной реактивностью к антителам adi-peg 20 для лечения рака | |
| JP2016519069A5 (enExample) | ||
| Yin et al. | Reconfiguring the architectures of cationic helical polypeptides to control non-viral gene delivery | |
| JP6243452B2 (ja) | アルブミン結合アルギニンデイミナーゼ融合たんぱく質を含有する医薬組成物 | |
| Goodarzi et al. | CD 44‐targeted docetaxel conjugate for cancer cells and cancer stem‐like cells: a novel hyaluronic acid‐based drug delivery system | |
| JP2013509861A5 (enExample) | ||
| JP2017006120A5 (enExample) | ||
| JP2017529366A5 (enExample) | ||
| JP2021505661A5 (enExample) | ||
| JP2016535009A5 (enExample) | ||
| JP2014521661A5 (enExample) | ||
| JP2016521688A5 (enExample) | ||
| US10202421B2 (en) | Tumor-targeting compounds | |
| CN111818937A (zh) | 使用天冬酰胺酶的治疗方法 | |
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| Pourhadi et al. | Expression, purification, and cytotoxic evaluation of IL24-BR2 fusion protein | |
| MX2020006671A (es) | Proteinas de fusion. | |
| Hu et al. | Targeted modification of the cationic anticancer peptide HPRP-A1 with iRGD to improve specificity, penetration, and tumor-tissue accumulation | |
| WO2008100482A3 (en) | Peptides that target to tumor blood vessels of lung cancer and applications thereof | |
| CN106589131A (zh) | 融合蛋白4D5Fv-PE25及其制备方法和用途 | |
| MX2012011668A (es) | Peptidos cdca5 y vacunas que incluyen los mismos. | |
| Ghavimi et al. | Exploring the potential of anticancer peptides as therapeutic agents for cancer treatment | |
| JP2019519536A5 (enExample) | ||
| Sheng et al. | An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation |